↓ Skip to main content

Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab

Overview of attention for article published in Therapeutics and Clinical Risk Management, October 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
3 X users

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
13 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Early intervention in the treatment of rheumatoid arthritis: focus on tocilizumab
Published in
Therapeutics and Clinical Risk Management, October 2013
DOI 10.2147/tcrm.s35784
Pubmed ID
Authors

Sedat Yilmaz, Ismail Simsek

Abstract

Tocilizumab is a fully humanized monoclonal antibody against interleukin-6 receptors that was approved for the treatment of patients with rheumatoid arthritis (RA). Several lines of evidence, obtained both from conventional disease-modifying anti-rheumatic drugs (DMARDs) and tumor necrosis factor (TNF) inhibitors, have supported the concept of "window of opportunity" as showing that these therapies consistently work better in early disease as compared to established RA. This review addresses the question of whether a window of opportunity gained with conventional DMARDs and TNF inhibitors can also be achieved with tocilizumab. To this end, data regarding the use of tocilizumab in early RA patients are summarized. Currently available data suggest that the earlier the treatment with tocilizumab, the better the clinical outcome can be, which may have implications for various aspects of RA treatment strategies.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 8%
Unknown 12 92%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 38%
Student > Bachelor 2 15%
Student > Ph. D. Student 2 15%
Professor 1 8%
Student > Doctoral Student 1 8%
Other 1 8%
Unknown 1 8%
Readers by discipline Count As %
Medicine and Dentistry 8 62%
Biochemistry, Genetics and Molecular Biology 1 8%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Social Sciences 1 8%
Computer Science 1 8%
Other 0 0%
Unknown 1 8%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2013.
All research outputs
#16,725,132
of 25,388,229 outputs
Outputs from Therapeutics and Clinical Risk Management
#814
of 1,323 outputs
Outputs of similar age
#131,732
of 217,590 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#6
of 14 outputs
Altmetric has tracked 25,388,229 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 217,590 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 7th percentile – i.e., 7% of its contemporaries scored the same or lower than it.